Primary endpoint analysis at 1 year showed better maintenance of erectile function and pad-free continence with TULSA than with robotic radical prostatectomy. Peri-procedural metrics favored TULSA, ...

TORONTO, March 27, 2026 (GLOBE NEWSWIRE)-- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Profound Medical (NASDAQ:PROF) and Telix Pharmaceuticals (NASDAQ:TLX) have signed a co-education agreement aimed at increasing physician awareness of how advanced diagnostic imaging can support ...

Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies ...

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures, is ...

In a randomized trial, half of patients who received TULSA maintained both pad-free continence and erections at 6 months compared with one-quarter who had RP. Magnetic resonance imaging (MRI)-guided ...

A new randomized clinical trial found that men with localized, intermediate‑risk prostate cancer recovered faster and experienced less short‑term impact on their daily lives when treated with ...

TULSA reduces tumor volume and PSA levels, improving urinary and sexual function in prostate cancer patients. Five-year TACT study data shows 80% of patients had no significant disease after one year, ...

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative ...